JP2010515427A5 - - Google Patents

Download PDF

Info

Publication number
JP2010515427A5
JP2010515427A5 JP2009534885A JP2009534885A JP2010515427A5 JP 2010515427 A5 JP2010515427 A5 JP 2010515427A5 JP 2009534885 A JP2009534885 A JP 2009534885A JP 2009534885 A JP2009534885 A JP 2009534885A JP 2010515427 A5 JP2010515427 A5 JP 2010515427A5
Authority
JP
Japan
Prior art keywords
sequence
amino acid
seq
acid residues
humanized antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2009534885A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010515427A (ja
JP5795833B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2007/082647 external-priority patent/WO2008070344A2/en
Publication of JP2010515427A publication Critical patent/JP2010515427A/ja
Publication of JP2010515427A5 publication Critical patent/JP2010515427A5/ja
Application granted granted Critical
Publication of JP5795833B2 publication Critical patent/JP5795833B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2009534885A 2006-10-27 2007-10-26 スフィンゴシン−１−リン酸と結合させるための組成物および方法 Active JP5795833B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US85497106P 2006-10-27 2006-10-27
US60/854,971 2006-10-27
PCT/US2007/082647 WO2008070344A2 (en) 2006-10-27 2007-10-26 Compositions and methods for binding sphingosine-1-phosphate

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2015004493A Division JP6053834B2 (ja) 2006-10-27 2015-01-13 スフィンゴシン−１−リン酸と結合させるための組成物および方法

Publications (3)

Publication Number Publication Date
JP2010515427A JP2010515427A (ja) 2010-05-13
JP2010515427A5 true JP2010515427A5 (de) 2011-09-15
JP5795833B2 JP5795833B2 (ja) 2015-10-14

Family

ID=39492938

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2009534885A Active JP5795833B2 (ja) 2006-10-27 2007-10-26 スフィンゴシン−１−リン酸と結合させるための組成物および方法
JP2015004493A Active JP6053834B2 (ja) 2006-10-27 2015-01-13 スフィンゴシン−１−リン酸と結合させるための組成物および方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2015004493A Active JP6053834B2 (ja) 2006-10-27 2015-01-13 スフィンゴシン−１−リン酸と結合させるための組成物および方法

Country Status (18)

Country Link
US (6) US7829674B2 (de)
EP (1) EP2087002B1 (de)
JP (2) JP5795833B2 (de)
KR (1) KR101581279B1 (de)
CN (2) CN101679506B (de)
AU (1) AU2007329759B2 (de)
BR (1) BRPI0718118A2 (de)
CA (1) CA2667574A1 (de)
DK (1) DK2087002T3 (de)
ES (1) ES2524059T3 (de)
IL (1) IL198379A (de)
MX (1) MX2009004532A (de)
PL (1) PL2087002T3 (de)
PT (1) PT2087002E (de)
RU (1) RU2460541C2 (de)
SI (1) SI2087002T1 (de)
WO (1) WO2008070344A2 (de)
ZA (1) ZA200902860B (de)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140186339A1 (en) * 2006-10-27 2014-07-03 Lpath, Inc. Compositions and methods for treating ocular diseases and conditions
US8444970B2 (en) * 2006-10-27 2013-05-21 Lpath, Inc. Compositions and methods for treating ocular diseases and conditions
WO2009108633A2 (en) * 2008-02-25 2009-09-03 Expression Drug Designs, Llc. Sphingosine 1-phosphate antagonism
US8212010B2 (en) 2008-02-25 2012-07-03 Expression Drug Designs, Llc Sphingosine 1-phosphate antagonism
WO2009124294A2 (en) * 2008-04-05 2009-10-08 Lpath, Inc. Pharmaceutical compositions for binding sphingosine-1-phosphate
US8444976B2 (en) 2008-07-02 2013-05-21 Argen-X B.V. Antigen binding polypeptides
GB2461546B (en) * 2008-07-02 2010-07-07 Argen X Bv Antigen binding polypeptides
US8401799B2 (en) * 2008-12-05 2013-03-19 Lpath, Inc. Antibody design using anti-lipid antibody crystal structures
AU2009322185A1 (en) * 2008-12-05 2011-07-21 Lpath, Inc. Antibody design using anti-lipid antibody crystal structures
WO2010098863A1 (en) * 2009-02-26 2010-09-02 Lpath, Inc. Humanized platelet activating factor antibody design using anti-lipid antibody templates
US20120282654A1 (en) * 2009-04-29 2012-11-08 Schering Corporation Antibody purification
NZ597809A (en) 2009-08-06 2014-05-30 Genentech Inc Method to improve virus removal in protein purification
GB2476681B (en) 2010-01-04 2012-04-04 Argen X Bv Humanized camelid VH, VK and VL immunoglobulin domains
US20110212088A1 (en) * 2010-02-26 2011-09-01 Sabbadini Roger A Anti-paf antibodies
US20130079309A1 (en) * 2010-03-03 2013-03-28 The Board Of Trustees Of The University Of Illinois Method Of Treating Acute Lung Injury Using Sphingosine 1 Phosphate Analogs Or Sphingosine 1 Phosphate Receptor Agonists
US9102718B2 (en) * 2010-04-30 2015-08-11 Lpath, Inc. Anti-S1P antibody treatment of patients with ocular disease
CA2801890A1 (en) * 2010-06-06 2012-05-03 Lpath, Inc. Combinations of anti-s1p antibodies and sphingolipid pathway inhibitors
US8747844B2 (en) 2010-07-30 2014-06-10 Saint Louis University Methods of treating pain
US20130259851A1 (en) * 2010-12-01 2013-10-03 Universitat Zurich Use of prokaryotic sphingosine-1-phosphate lyases and of sphingosine-1-phosphate lyases lacking a transmembrane domain for treating hyperproliferative and other diseases
JP5766958B2 (ja) * 2011-01-21 2015-08-19 オリンパス株式会社 顕微鏡システム、情報処理装置、及び情報処理プログラム
WO2012162392A1 (en) * 2011-05-23 2012-11-29 Timothy Hla Endothelium protective materials and methods of use
JP2014524581A (ja) 2011-08-19 2014-09-22 マルバーン インストゥルメンツ リミテッド 微粒子のデュアルモード特徴付け
CN107973856B (zh) * 2012-07-04 2021-11-23 弗·哈夫曼-拉罗切有限公司 共价连接的抗原-抗体缀合物
EP3339328A1 (de) 2012-07-04 2018-06-27 F. Hoffmann-La Roche AG Anti-biotin-antikörper und verwendungsverfahren
HUE029435T2 (en) 2012-07-04 2017-02-28 Hoffmann La Roche Anti-theophylline antibodies and methods of their application
GB201300684D0 (en) 2013-01-15 2013-02-27 Apitope Int Nv Peptide
EP2787006B1 (de) 2013-04-02 2018-02-28 Miltenyi Biotec GmbH Anti-CD8 Antikörper mit kalziumabhängiger Bindung
CA2930046A1 (en) 2014-01-03 2015-07-09 F. Hoffmann-La Roche Ag Covalently linked polypeptide toxin-antibody conjugates
PL3089996T3 (pl) 2014-01-03 2021-12-13 F. Hoffmann-La Roche Ag Dwuswoiste przeciwciała przeciw haptenowi/przeciw receptorowi występującemu w barierze krew-mózg, ich kompleksy i ich zastosowanie jako przenośniki wahadłowe występujące w barierze krew-mózg
MX2016008189A (es) 2014-01-03 2016-09-29 Hoffmann La Roche Conjugados helicoidales-anticuerpo anti-helicoidal unidos covalentemente y usos de los mismos.
WO2015197736A1 (en) 2014-06-26 2015-12-30 F. Hoffmann-La Roche Ag Anti-brdu antibodies and methods of use
EP3215246A1 (de) * 2014-11-06 2017-09-13 Merck Patent GmbH Aktivkohle zum entfernen von auslaugbaren und/oder extraktionsfähigen stoffen
US9754383B1 (en) * 2014-12-22 2017-09-05 Flagship Biosciences, Inc. Automated methods for assessment of celiac disease
WO2017015334A1 (en) 2015-07-21 2017-01-26 Saint Louis University Compositions and methods for diagnosing and treating endometriosis-related infertility
CN105820250B (zh) * 2016-04-29 2019-04-30 中国人民解放军第四军医大学 一种抗basigin人源化抗体及其应用
JP2020501503A (ja) 2016-12-15 2020-01-23 ソシエテ・デ・プロデュイ・ネスレ・エス・アー コンパニオンアニマルにおけるリン又は酵素を調節する組成物及び方法
ES2957464T3 (es) 2017-04-14 2024-01-19 Univ Arizona Composiciones y métodos para tratar fibrosis pulmonar
WO2018191747A1 (en) 2017-04-14 2018-10-18 Arizona Board Of Regents On Behalf Of The University Of Arizona Compositions and methods for treating pulmonary arterial hypertension

Family Cites Families (145)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1073471B (de) 1958-09-02 1960-01-21 Chemische Werke Hüls Aktiengesellschaft, Marl (Kr. Recklinghausen) Verfahren zur Herstellung von Azelainsäure
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
GB1573212A (en) 1976-04-15 1980-08-20 Technicon Instr Immunoassay for gentamicin
USRE30985E (en) 1978-01-01 1982-06-29 Serum-free cell culture media
US4275149A (en) 1978-11-24 1981-06-23 Syva Company Macromolecular environment control in specific receptor assays
US4318980A (en) 1978-04-10 1982-03-09 Miles Laboratories, Inc. Heterogenous specific binding assay employing a cycling reactant as label
JPS6023084B2 (ja) 1979-07-11 1985-06-05 味の素株式会社 代用血液
US4376110A (en) 1980-08-04 1983-03-08 Hybritech, Incorporated Immunometric assays using monoclonal antibodies
US4485045A (en) 1981-07-06 1984-11-27 Research Corporation Synthetic phosphatidyl cholines useful in forming liposomes
US4640835A (en) 1981-10-30 1987-02-03 Nippon Chemiphar Company, Ltd. Plasminogen activator derivatives
US4560655A (en) 1982-12-16 1985-12-24 Immunex Corporation Serum-free cell culture medium and process for making same
US4657866A (en) 1982-12-21 1987-04-14 Sudhir Kumar Serum-free, synthetic, completely chemically defined tissue culture media
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4544545A (en) 1983-06-20 1985-10-01 Trustees University Of Massachusetts Liposomes containing modified cholesterol for organ targeting
US4767704A (en) 1983-10-07 1988-08-30 Columbia University In The City Of New York Protein-free culture medium
US4496689A (en) 1983-12-27 1985-01-29 Miles Laboratories, Inc. Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
SE455445B (sv) 1984-08-28 1988-07-11 Pharmacia Ab Antikroppar mot sialosyllaktotetraos (iv?723neuaclcose?714) och antikroppens resp antigenets anvendning vid tumordiagnostik
EP0173648A3 (de) 1984-08-30 1988-04-27 Ciba-Geigy Ag Monoklonale Antikörper gegen Glykokonjugate, Verfahren zu ihrer Herstellung und Verwendungen
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
US4879231A (en) 1984-10-30 1989-11-07 Phillips Petroleum Company Transformation of yeasts of the genus pichia
US4737456A (en) 1985-05-09 1988-04-12 Syntex (U.S.A.) Inc. Reducing interference in ligand-receptor binding assays
EP0206448B1 (de) 1985-06-19 1990-11-14 Ajinomoto Co., Inc. Hämoglobin, das an ein Poly(alkenylenoxid) gebunden ist
GB8516415D0 (en) 1985-06-28 1985-07-31 Celltech Ltd Culture of animal cells
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
US6548640B1 (en) 1986-03-27 2003-04-15 Btg International Limited Altered antibodies
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
GB8607679D0 (en) * 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US4927762A (en) 1986-04-01 1990-05-22 Cell Enterprises, Inc. Cell culture medium with antioxidant
GB8610600D0 (en) 1986-04-30 1986-06-04 Novo Industri As Transformation of trichoderma
US4791192A (en) 1986-06-26 1988-12-13 Takeda Chemical Industries, Ltd. Chemically modified protein with polyethyleneglycol
US5567610A (en) 1986-09-04 1996-10-22 Bioinvent International Ab Method of producing human monoclonal antibodies and kit therefor
US4937232A (en) 1986-09-15 1990-06-26 Duke University Inhibition of protein kinase C by long-chain bases
US4816450A (en) 1986-09-15 1989-03-28 Duke University Inhibition of protein kinase C by long-chain bases
WO1988007089A1 (en) 1987-03-18 1988-09-22 Medical Research Council Altered antibodies
US5204244A (en) 1987-10-27 1993-04-20 Oncogen Production of chimeric antibodies by homologous recombination
DE3741056A1 (de) 1987-12-04 1989-08-24 Behringwerke Ag Manumycin-derivate, verfahren zu ihrer herstellung und ihre verwendung
AU632065B2 (en) 1988-09-23 1992-12-17 Novartis Vaccines And Diagnostics, Inc. Cell culture medium for enhanced cell growth, culture longevity and product expression
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5175384A (en) 1988-12-05 1992-12-29 Genpharm International Transgenic mice depleted in mature t-cells and methods for making transgenic mice
US20040049014A1 (en) 1988-12-28 2004-03-11 Protein Design Labs, Inc. Humanized immunoglobulins
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
EP0402226A1 (de) 1989-06-06 1990-12-12 Institut National De La Recherche Agronomique Transformationsvektoren für Hefe Yarrowia
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5229275A (en) 1990-04-26 1993-07-20 Akzo N.V. In-vitro method for producing antigen-specific human monoclonal antibodies
US5122469A (en) 1990-10-03 1992-06-16 Genentech, Inc. Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins
US5151360A (en) 1990-12-31 1992-09-29 Biomembrane Institute Effect of n,n,n-trimethylsphingosine on protein kinase-c activity, melanoma cell growth in vitro, metastatic potential in vivo and human platelet aggregation
US5248824A (en) 1990-12-31 1993-09-28 The Biomembrane Institute Method of preparing N,N,N-trimethylsphingosine
US5137919A (en) 1990-12-31 1992-08-11 Biomembrane Institute Effect of N,N,N,-trimethylsphingosine on protein kinase C activity melanoma cell growth in vitro; metastatic potential in vivo and human platelet aggregation
US5677288A (en) 1991-05-15 1997-10-14 Cypros Pharmaceutical Corporation Use of aminoglycosides to protect against excitotoxic neuron damage
EP0519596B1 (de) 1991-05-17 2005-02-23 Merck & Co. Inc. Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen
CA2103059C (en) 1991-06-14 2005-03-22 Paul J. Carter Method for making humanized antibodies
US5430160A (en) 1991-09-23 1995-07-04 Florida State University Preparation of substituted isoserine esters using β-lactams and metal or ammonium alkoxides
US5565332A (en) 1991-09-23 1996-10-15 Medical Research Council Production of chimeric antibodies - a combinatorial approach
DK1136556T3 (da) 1991-11-25 2005-10-03 Enzon Inc Fremgangsmåde til fremstilling af multivalente antigen-bindende proteiner
US5932448A (en) 1991-11-29 1999-08-03 Protein Design Labs., Inc. Bispecific antibody heterodimers
US5777085A (en) 1991-12-20 1998-07-07 Protein Design Labs, Inc. Humanized antibodies reactive with GPIIB/IIIA
ATE244763T1 (de) 1992-02-11 2003-07-15 Cell Genesys Inc Erzielen von homozygotem durch zielgerichtete genetische ereignisse
US5714350A (en) 1992-03-09 1998-02-03 Protein Design Labs, Inc. Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region
US6129914A (en) 1992-03-27 2000-10-10 Protein Design Labs, Inc. Bispecific antibody effective to treat B-cell lymphoma and cell line
US5573905A (en) 1992-03-30 1996-11-12 The Scripps Research Institute Encoded combinatorial chemical libraries
US5260288A (en) 1992-04-03 1993-11-09 The Biomembrane Institute Method for inhibition of cell motility by sphingosine-1-phosphate and derivatives
US5369030A (en) 1992-09-11 1994-11-29 Duke University Method of inducing cellular differentiations and altering cell phenotype using ceramide analogs
GB9223377D0 (en) 1992-11-04 1992-12-23 Medarex Inc Humanized antibodies to fc receptors for immunoglobulin on human mononuclear phagocytes
US6210671B1 (en) 1992-12-01 2001-04-03 Protein Design Labs, Inc. Humanized antibodies reactive with L-selectin
US5444087A (en) 1993-10-19 1995-08-22 Bristol-Myers Squibb Company Manumycin compounds
EP0729359A4 (de) 1993-11-15 1999-06-02 Baker Med Res Inst Verfahren zur behandlung von herzfunktions-störungen und dafür verwendbare pharmazeutische präparate
GB9325182D0 (en) 1993-12-08 1994-02-09 T Cell Sciences Inc Humanized antibodies or binding proteins thereof specific for t cell subpopulations exhibiting select beta chain variable regions
ES2149350T3 (es) 1994-02-02 2000-11-01 Liposome Co Inc Compuestos y liposomas farmaceuticamente activos y metodos para su utilizacion.
US5430169A (en) 1994-02-14 1995-07-04 The United States Of America Represented By The Department Of Health And Human Services Method for preparation of sphingoid bases
US5585476A (en) 1994-02-15 1996-12-17 Maclennan; Alexander J. Molecular cloning and expression of G-protein coupled receptors
US5627171A (en) 1994-04-11 1997-05-06 Oncomembrane, Inc. Sphingosine-1-phosphate/trimethylsphingosine composition
US5534615A (en) 1994-04-25 1996-07-09 Genentech, Inc. Cardiac hypertrophy factor and uses therefor
US6323201B1 (en) 1994-12-29 2001-11-27 The Regents Of The University Of California Compounds for inhibition of ceramide-mediated signal transduction
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US6096871A (en) 1995-04-14 2000-08-01 Genentech, Inc. Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life
US7060808B1 (en) 1995-06-07 2006-06-13 Imclone Systems Incorporated Humanized anti-EGF receptor monoclonal antibody
US5667337A (en) 1995-09-15 1997-09-16 Lazes; Richard J. Rotating containment and repelling boom and method for confining a material floatable on a liquid surface
WO1997010817A1 (en) 1995-09-20 1997-03-27 The Regents Of The University Of Michigan Amino ceramide-like compounds and therapeutic methods of use
WO2001004108A1 (en) 1999-07-09 2001-01-18 Regents Of The University Of Michigan Amino ceramide-like compounds and therapeutic methods of use
JPH09110722A (ja) 1995-10-20 1997-04-28 Toray Ind Inc 抗腫瘍活性物質の腫瘍細胞内導入用イムノリポソーム及びその調製法
US5882644A (en) 1996-03-22 1999-03-16 Protein Design Labs, Inc. Monoclonal antibodies specific for the platelet derived growth factor β receptor and methods of use thereof
US5834597A (en) 1996-05-20 1998-11-10 Protein Design Labs, Inc. Mutated nonactivating IgG2 domains and anti CD3 antibodies incorporating the same
US5830916A (en) 1996-05-23 1998-11-03 Duke University Inhibitor of ceramidase
DE19621038A1 (de) 1996-05-24 1997-11-27 Boehringer Ingelheim Kg Aminoguanidine, Verfahren zu ihrer Herstellung und Arzneimittel, die diese Verbindungen enthalten
AU718171B2 (en) 1996-07-19 2000-04-06 Takara Bio Inc. Methods for producing sphingolipids and sphingolipid derivatives
US6013256A (en) 1996-09-24 2000-01-11 Protein Design Labs, Inc. Method of preventing acute rejection following solid organ transplantation
US6140060A (en) 1996-12-12 2000-10-31 Chun; Jerold J. M. Cloned lysophosphatidic acid receptors
US5919687A (en) 1996-12-24 1999-07-06 John Hopkins University Recombinant N-SMases and nucleic acids encoding same
KR100559817B1 (ko) 1997-03-12 2006-03-10 다카라 바이오 가부시키가이샤 스핑고신 유사화합물
DE69842017D1 (de) 1997-06-10 2011-01-05 Lpath Inc Verfahren zum frühzeitigen nachweis herzerkrankungen
JP2001512682A (ja) 1997-08-11 2001-08-28 メモレック シュトッフェル ゲゼルシャフト ミット ベシュレンクテル ハフツング 中性スフィンゴミエリナーゼ
US5989803A (en) 1997-09-05 1999-11-23 The Trustees Of Columbia University In The City Of New York Method for treating a subject suffering from a condition associated with an extracellular zinc sphingomyelinase
US6649362B2 (en) 1997-09-08 2003-11-18 Medvet Science Pty. Ltd. Screening method for an agent having an effect on a sphingosine kinase signaling pathway
US6239297B1 (en) 1997-09-11 2001-05-29 Takara Shuzo Co., Ltd. Sphingosine derivatives and medicinal composition
US6423527B1 (en) 1997-09-29 2002-07-23 Children's Hospital Medical Center Of Northern California Sphingosine-1-phosphate lyase polypeptides, polynucleotides and modulating agents and methods of use therefor
DK1034298T3 (da) 1997-12-05 2012-01-30 Scripps Research Inst Humanisering af murint antistof
US6057126A (en) 1997-12-24 2000-05-02 Allelix Biopharmaceuticals, Inc. Mammalian EDG-5 receptor homologs
EP1060256A1 (de) 1998-01-29 2000-12-20 Smithkline Beecham Plc Neue sphingosine-1 phosphate lyase
US6610835B1 (en) 1998-02-12 2003-08-26 Emory University Sphingolipid derivatives and their methods of use
CN1286692A (zh) 1998-02-16 2001-03-07 社团法人北里研究所 新的kf－1040物质和制备该物质的方法
WO1999046277A1 (en) 1998-03-09 1999-09-16 Smithkline Beecham Corporation HUMAN EDG-1c POLYNUCLEOTIDES AND POLYPEPTIDES AND METHODS OF USE
EP1071458A4 (de) 1998-03-13 2005-02-16 Dana Farber Cancer Inst Inc Humanisierter antikörper und dessen verwendungen
US6130067A (en) 1998-05-20 2000-10-10 Smithkline Beecham Corporation Human EDG3sb gene
EP1235913A2 (de) 1998-05-26 2002-09-04 Sarah Spiegel Sphingosin-kinase, klonierung, expression und verfahren zur anwendung
DE19828850A1 (de) 1998-06-27 1999-12-30 Gvs Ges Fuer Erwerb Und Verwer Sphingolipid-Desaturase
EP1091745B1 (de) 1998-06-29 2008-10-01 Children's Hospital Of Los Angeles Behandlung hyperproliferativer erkrankungen
DE19847149A1 (de) 1998-10-13 2000-04-20 Max Planck Gesellschaft Pseudo-Ceramide
EP1135415B1 (de) 1998-12-01 2010-08-11 Facet Biotech Corporation Humanisierte antikoerper gegen gamma-interferon
WO2000040262A1 (en) 1999-01-05 2000-07-13 The Flinders University Of South Australia Novel agents and methods for treatment and diagnosis of ocular disorders
WO2000052173A2 (en) 1999-03-02 2000-09-08 Nps Allelix Corp. Cloned human sphingosine kinase homologues
US6812335B1 (en) 1999-03-23 2004-11-02 The Regents Of The University Of California Human polypeptide receptors for lysophospholipids and sphingolipids and nucleic acids encoding the same
US6608185B1 (en) 1999-03-25 2003-08-19 Kitasato Institute Substances KF-1040T4A,KF-1040T4B, KF-1040T5A, and KF-1040T5B, and process for producing same
WO2000058448A1 (fr) 1999-03-26 2000-10-05 Takara Shuzo Co., Ltd. Gene de ceramidase
US7820718B1 (en) 1999-04-07 2010-10-26 Roger Williams Hospital Combinations of ceramide and chemotherapeutic agents for inducing cell death and uses thereof in treating cancer
JP2000293181A (ja) 1999-04-12 2000-10-20 Daiichikosho Co Ltd 歌詞画像描出機能に特徴を有するカラオケ装置
BR0010017A (pt) * 1999-04-28 2002-06-11 Univ Texas Composições e processos para o tratamento de câncer por inibição seletiva de vegf
ATE323153T1 (de) 1999-05-13 2006-04-15 Johnson & Johnson Pharm Res Sphingosinekinase
DE19924148A1 (de) 1999-05-26 2000-12-07 Univ Heidelberg Sphingomyelinasehemmer
WO2001004139A2 (en) 1999-07-13 2001-01-18 Smithkline Beecham Corporation Human axor29 receptor
IT1307786B1 (it) 1999-07-22 2001-11-19 Bracco Spa Analoghi di ceramidi, processo per la loro preparazione e loro usocome antitumorali.
BR0015138A (pt) 1999-10-28 2002-07-16 Warner Lambert Co Gene da esfingosina quinase humana
AU1548101A (en) 1999-11-24 2001-06-04 Sagami Chemical Research Center Sphingosine derivatives
WO2001055410A2 (en) 2000-01-28 2001-08-02 Musc Foundation For Research Development Ceramidase compositions and methods based thereon
US6306911B1 (en) 2000-02-07 2001-10-23 Ortho-Mcneil Pharmaceutical, Inc. Substituted amino acids as neutral sphingomyelinase inhibitors
JP2003521912A (ja) 2000-02-07 2003-07-22 メルク エンド カムパニー インコーポレーテッド 哺乳動物スフィンゴシン−１−リン酸ホスファターゼ
US6858427B2 (en) 2000-02-14 2005-02-22 Genentech, Inc. Sphingosine kinases
JP2001261575A (ja) 2000-03-13 2001-09-26 General Hospital Corp 血管収縮を調節する方法とその組成物
US20020037495A1 (en) 2000-03-23 2002-03-28 Gutierrez Juan Antonio High throughput screening for inhibitors of fatty acid, ergosterol, sphingolipid, or phospholipid synthesis in fungi
WO2001072701A1 (en) 2000-03-28 2001-10-04 The Liposome Company, Inc. Ceramide derivatives and method of use
AU2001255477A1 (en) 2000-04-19 2001-11-07 The Trustees Of Columbia University In The City Of New York Detection and treatment of atherosclerosis based on plasma sphingomyelin concentration
AUPQ744700A0 (en) 2000-05-11 2000-06-01 Medvet Science Pty. Ltd. A method of treatment and agents useful for same
US6571638B2 (en) 2000-06-30 2003-06-03 Sawtek, Inc. Surface-acoustic-wave pressure sensor and associated methods
US20030125533A1 (en) 2000-10-06 2003-07-03 Sophia Kossida Regulation of human sphingosine kinase-like protein
EP1363643A2 (de) 2000-12-22 2003-11-26 Medlyte, Inc. Zusammensetzungen und methoden zur behandlung und vorbeugung von kardiovaskulären erkrankungen und zur identifizierung therapeutischer mittel
US20020150582A1 (en) 2001-02-08 2002-10-17 Friedrichs Gregory S. Method of treating or inhibiting cellular injury or cell death
US7674580B2 (en) 2002-01-17 2010-03-09 Children's Hospital & Research Center At Oakland Compositions and methods for the modulation of sphingolipid metabolism and/or signaling
US7794713B2 (en) 2004-04-07 2010-09-14 Lpath, Inc. Compositions and methods for the treatment and prevention of hyperproliferative diseases
WO2006014802A2 (en) 2004-07-27 2006-02-09 Merck & Co., Inc. Canis sphingosine 1-phosphate receptor isoform 1
ES2410866T3 (es) * 2004-10-28 2013-07-03 Lpath, Inc. Composiciones y procedimientos para el tratamiento y prevención de enfermedades hiperproliferativas
US20110123440A1 (en) 2005-03-29 2011-05-26 Genevieve Hansen Altered Antibody FC Regions and Uses Thereof
US20080213274A1 (en) * 2005-10-28 2008-09-04 Sabbadini Roger A Compositions and methods for the treatment and prevention of fibrotic, inflammatory, and neovascularization conditions of the eye
US8444970B2 (en) * 2006-10-27 2013-05-21 Lpath, Inc. Compositions and methods for treating ocular diseases and conditions

Similar Documents

Publication Publication Date Title
JP2010515427A5 (de)
JP7019198B2 (ja) 補体関連疾患の予防及び治療のためのｃ５抗体及び方法
US11712470B2 (en) Human endothelin receptor antibody and use thereof
KR101600308B1 (ko) 조직 인자 경로 억제자에 대한 항체
JP3957765B2 (ja) 抗ｖｅｇｆ抗体
JPH11507535A (ja) 腫瘍の成長を抑制する抗体および抗体フラグメント類
KR20090005111A (ko) 항체의 혈중 동태를 제어하는 방법
JP6236478B2 (ja) 血清アミロイドｐ成分に特異的な抗原結合タンパク質
JP6410712B2 (ja) Ｉｌ−６結合分子
CN110475570A (zh) 抗人膜联蛋白a1抗体
AU2021202612B2 (en) Inhibition of platelet aggregation using anti-human GPVI antibodies
JP2021520195A (ja) Ｃ３結合薬及びその使用方法
EP3412688A1 (de) Thrombin-antikörper, antigenbindendes fragment und pharmazeutische verwendung davon
AU2020350715A1 (en) GIPR antibody and fusion protein between same and GLP-1, and pharmaceutical composition and application thereof
KR20210102946A (ko) 항il-17a 항체 및 이의 응용
US20230250191A1 (en) Anti-ige engineered antibody and application thereof
WO2021226442A2 (en) Therapeutic uses of c3-binding agents
CN110655577A (zh) APJ抗体及其与Elabela的融合蛋白质，以及其药物组合物和应用
KR20240022546A (ko) 항il-36r 항체 및 그의 사용
JP2020002075A (ja) ヒトとラットの腎上皮ポドプラニンに結合する交差性抗体及びその可変領域断片